Predict your next investment

HEALTHCARE | Biotechnology
scienion.com

See what CB Insights has to offer

Founded Year

2001

Stage

Acquired | Acquired

Valuation

$0000 

About Scienion

Scienion offers complete solutions for parallel bioanalytics and high throughput production/screening of microarrays in genomics and proteomics. The company specializes in ultra low volume liquid handling, particularly for precious and sensitive compounds of biological or chemical origin.On August 20th, 2020, Scienion was acquired by Cellink at a valuation of $94.83M.

Scienion Headquarter Location

Volmerstrasse 7b

Berlin, D-12489,

Germany

+49 (0) 30 6392 17 00

Latest Scienion News

BICO Announces Million-Dollar Contract for 3D Printed Joint Implants

Dec 14, 2021

BICO Announces Million-Dollar Contract for 3D Printed Joint Implants December 13, 2021 Danish AM Hub is a national 3D printing group that organizes a large meet-up with the goal of educating and aiding its members in all things 3D printing. Several places... December 6, 2021 Senior vice president of Strategic Growth at Stratasys, Pat Carey talks to us about the company’s new product portfolio. What does it mean for partners and customers that the company... November 29, 2021 Having previously worked for Bond3D and Admatec, Michiel de Bruijcker is now doing something very new and exciting in 3D printing. With Poly Products, he’s printing large-scale structures and parts. Using... Objectify 3DPOD Episode 86: Pat Carey, Stratasys SVP of Strategic Growth 3DPOD Episode 85: Large Format 3D Printing with Poly Products’ Michiel de Bruijcker Search Contact us below to learn more Share this Article For five years, Nanochon has been developing a 3D-printed implantable device and novel nanomaterial to treat cartilage loss and damage in joints as an alternative to knee replacements. Now, BICO ( formerly Cellink ) and the Washinton D.C.-based MedTech startup are teaming up to develop 3D printed regenerative joint implants that could start clinical trials as soon as 2023. As part of the deal, Nanochon will purchase $1.5 million worth of products and services from BICO’s bio automation services subsidiary Scienion to create the joint implants, which promise faster and more successful recoveries for patients while reducing costs to health providers, payers, and patients. At the same time, BICO will invest $400,000 in Nanochon’s Seed funding round to help advance its regenerative medicine technology, scale its manufacturing processes, and accelerate clinical trials. The deal aligns with a crucial part of BICO’s Next Generation Core Industrial Ecosystems that enable tissue engineering , diagnostics, multi-omics , and cell line development. Nanochon has developed highly-engineered implants for clinical trials. Image courtesy of Nanochon. “Nanochon’s approach to regenerative joint replacement has the potential to improve the lives of tens of millions of people each year,” explained Erik Gatenholm, CEO and co-founder of BICO. “We’re thrilled to leverage BICO’s bio automation manufacturing and technology expertise to help bring this product to millions of patients around the world.” The agreement will provide BICO’s company Scienion, the opportunity to become Nanochon’s contract manufacturer for cartilage resurfacing implants. The process will leverage several key technologies from the BICO portfolio to enable what is described as a “first of its kind solution” and will also make Scienion a key manufacturing partner for Nanochon over the coming decade. Founded in 2016 by mechanical engineer and life science entrepreneur Ben Holmes and tissue engineer Nathan Castro, Nanochon targets 3D printed products for soft tissue repair in orthopedics. Their first proprietary product, Chondrograft, is a 3D printed polymer implant awaiting FDA approval that fills and regenerates damaged areas of the cartilage surface in joints, typically associated with sports injuries and osteoarthritis. If left untreated, these injuries can cause the patient pain, lead to advanced joint disease, and the need for knee replacement surgery. So Nanochon’s ultimate goal is to commercialize a treatment with much better outcomes and be widely accessible to patients and surgeons. Built upon research for scaling up existing experimental materials to meet clinical needs, Holmes and Castro saw potential in a composite material called nanostructured polyurethane (nPU) as a cartilage replacement due to its unique chemical and physical properties, which allow it to support rapid stem cell growth and tissue formation. Holmes was exploring strategies for scaling up existing experimental materials to meet clinical needs and discovered that 3D printed nPU has mechanical properties similar to cartilage and can support vascularized bone growth, which is essential for integrating any joint implant and its clinical success. Nanochon has developed highly-engineered implants for clinical trials. Image courtesy of Nanochon. The duo developed the new proprietary material for a new type of cartilage implant that can replace lost cartilage on a short-term basis and can fuse with the body in the longer term. The implant is targeted at knee injury patients who are younger and more active, typically under 55 years old. The startup detected that most of these patients want to return to more strenuous activities. Current treatment options (like metallic joint replacements) are not good enough, mainly due to invasiveness, complications, or general lack of effectiveness. Almost one million hip and knee replacement surgeries are performed in the United States every year alone, projected to grow 673% to 3.5 million procedures per year. In fact, the U.S. Centers for Medicare & Medicaid Services estimates that aging Americans will drive annual healthcare spending to $6 trillion by 2027, with much of that coming from aging-related disorders like osteoporosis. Worldwide, estimated orthopedic joint replacement surgeries are roughly 7.7 million, according to GlobalSurg , with a market size of $20 billion in 2019. How the Nanochon medical device is used in joints. Image courtesy of Nanochon. Hip and knee replacements are the most commonly performed joint replacements today. Still, they are expected to fail after 15-20 years due to a lack of organic cartilage growth and the highly disruptive nature of the surgery. Instead, Nanochon’s novel regenerative method would ideally solve this by replacing a highly invasive replacement surgery with a minimally invasive procedure, where 3D printed structures made of a novel polymer nanomaterial are implanted into damaged cartilage to promote healthy cartilage growth. Working towards that goal, Nanochon has worked with clinical and research partners to conduct several validating and de-risking studies, including a small animal study with Matthew Oetgen, the Chief of Orthopedic Surgery and Sports Medicine at Children’s National Medical Center, and an extensive animal proof of concept trial with Colorado clinical trial management service company CARE Research . Additionally, in 2017 Nanochon received a Phase I SBIR from the National Science Foundation to develop a production-ready 3D printed medical device for cartilage repair in the knee made from new tissue growth materials and designs compatible with selective laser sintering. The team also executed a manufacturing feasibility study with Belgian 3D printing company Materialise , a leader in 3D printed implants. However, through this new sales deal, Nanochon could become a springboard for future implant designs and cartilage restoration initiatives. Likewise, BICO will continue leveraging 3D printing for healthcare solutions, incorporating even more companies into its customer portfolio.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Scienion

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Scienion is included in 1 Expert Collection, including Omics.

O

Omics

1,213 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Scienion Patents

Scienion has filed 8 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Cell biology
  • Colloidal chemistry
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/21/2017

5/11/2021

Cell biology, Quantum mechanics, Fluid dynamics, Colloidal chemistry, Biotechnology

Grant

Application Date

3/21/2017

Grant Date

5/11/2021

Title

Related Topics

Cell biology, Quantum mechanics, Fluid dynamics, Colloidal chemistry, Biotechnology

Status

Grant

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.